Literature DB >> 2554873

Mechanisms of positive inotropic effects.

H Scholz1.   

Abstract

This review deals with the principal mechanisms which are known to play a role in positive inotropism: 1) The myoplasmic Ca2+ concentration may be increased by increases in cyclic AMP. Beside receptor-mediated stimulation (isoprenaline) or direct stimulation (forskolin) of the adenylate cyclase, the cyclic AMP may be increased by phosphodiesterase inhibition; 2) Cyclic AMP-independent activation of Ca2+ channels can be brought about by alpha-adrenergic agents (phenylephrine) or so-called calcium agonists; 3) Only a small increase in myoplasmic Na+ concentration can greatly enhance the force of contraction by an increase in the intracellular Ca2+ concentration. This is possible by inhibition of the Na+/K+-ATPase (glycosides) or by prolongation of the open state of Na+ channels (DPI 201-106); 4) A direct inhibition of the Na+/Ca2+ exchange has been discussed for amiloride; 5) A prolongation of the action potential induced by K+ channel-inhibiting agents such as 4-amino-pyridine may increase the myoplasmic Ca2+ concentration by a prolongation of the slow Ca2+ inward current; 6) An increased Ca2+ sensitivity of the contractile proteins has been demonstrated for a number of compounds in vitro; the contribution of such an effect to the overall positive inotropism is unknown because a calcium sensitizer without any effects on calcium or sodium movements is not yet available.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554873     DOI: 10.1007/BF02650341

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  6 in total

Review 1.  Cardioactive substances that prolong the open state of sodium channels.

Authors:  P Honerjäger
Journal:  Rev Physiol Biochem Pharmacol       Date:  1982       Impact factor: 5.545

2.  Phosphodiesterase-inhibiting properties of newer inotropic agents.

Authors:  H Scholz; W Meyer
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

3.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

4.  Mechanism of action and cardiotonic activity of a new phosphodiesterase inhibitor, the benzimidazole derivative adibendan (BM 14.478), in guinea-pig hearts.

Authors:  T Bethke; D Brunkhorst; H von der Leyen; W Meyer; R Nigbur; H Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

5.  Alpha-1 adrenoceptor-mediated positive inotropic effect and inositol trisphosphate increase in mammalian heart.

Authors:  J Scholz; B Schaefer; W Schmitz; H Scholz; M Steinfath; M Lohse; U Schwabe; J Puurunen
Journal:  J Pharmacol Exp Ther       Date:  1988-04       Impact factor: 4.030

6.  Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure.

Authors:  M D Feldman; L Copelas; J K Gwathmey; P Phillips; S E Warren; F J Schoen; W Grossman; J P Morgan
Journal:  Circulation       Date:  1987-02       Impact factor: 29.690

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.